Novartis Glivec Make It Through NICE For GISTs With Expanded Label
This article was originally published in The Pink Sheet Daily
Executive Summary
After a prior rejection, Britain’s NICE has backed Novartis’ Glivec for KIT (CD117)-positive GISTS, even accepting an expanded-treatment duration of three years compared to the original single year.